CEL-SCI logo

CVM - CEL-SCI News Story

$5.7 -0.5  -7.6%

Last Trade - 7:36pm

Small Cap
Market Cap £197.9m
Enterprise Value £176.8m
Revenue £n/a
Position in Universe 4446th / 7414

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CEL-SCI Corporation - CVM

Thu 8th July, 2021 1:21am
For best results when printing this announcement, please click on link below:

NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating
claims on behalf of investors of CEL-SCI Corporation (“CEL-SCI” or the
“Company”) (NYSE: CVM). Such investors are advised to contact Robert S.
Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether CEL-SCI and certain of its officers and/or
directors have engaged in securities fraud or other unlawful business

[Click here for information about joining the class action]

On June 28, 2021, CEL-SCI issued a press release announcing that the Phase 3
study for the Company’s Multikine (leukocyte interleukin) immunotherapy
candidate missed its primary endpoint for primary (previously untreated)
squamous cell carcinoma of the head and neck. 

On this news, CEL-SCI’s stock price fell $11.39 per share, or 45.41%, to
close at $13.69 per share on June 28, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris
is acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 80 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com

Robert S. Willoughby
Pomerantz LLP

GlobeNewswire, Inc. 2021
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.